金融界消息 截至2025年8月5日收盘，回盛生物（300871）报收于24.82元，上涨1.85%，换手率 12.87%，成交量26.04万手，成交金额6.36亿元。 来源：金融界 天眼查商业履历信息显示，武汉回盛生物科技股份有限公司，成立于2002年，位于武汉市，是一家以从 事医药制造业为主的企业。企业注册资本17919.4432万人民币，实缴资本8000万人民币。公司法定代表 人为张卫元。 资金流向方面，今日主力资金净流入3665.05万元，占比成交额5.76%。其中，超大单净流入127.53万 元、占成交额0.2%，大单净流入3537.52万元、占成交额5.56%，中单净流出流入3792.84万元、占成交 额5.96%，小单净流出7457.89万元、占成交额11.73%。 通过天眼查大数据分析，武汉回盛生物科技股份有限公司共对外投资了13家企业，参与招投标项目50 次，知识产权方面有商标信息115条，专利信息63条，此外企业还拥有行政许可47个。 回盛生物最新一期业绩显示，截至2025一季报，公司营业总收入3.99亿元、同比增长92.96%，归属净利 润4449.70万元，同比增长371.23%，扣非净 ...

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]

证券之星消息，7月31日动物保健板块较上一交易日下跌0.43%，大禹生物领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1611.97万元，游资资金净流出6281.9万元，散户 资金净流入7893.87万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300871 回盛生物 | | 6787.00万 | 7.85% | -4042.91万 | -4.68% | -2744.09万 | -3.17% | | 600201 | 生物股份 | 2619.98万 | 9.14% | -534.51万 | -1.86% | -2085.47万 | -7.28% | | 002868 *ST绿康 | | 940.97万 | 10.50% | -518.20 ...

（文章来源：每日经济新闻） 每经AI快讯，7月31日，创新药概念股持续活跃，南新制药20%涨停，奇正藏药、汉商集团涨停，海特 生物、安科生物、回盛生物、振东制药、特宝生物、珍宝岛等涨超5%。 ...

Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanjing New Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Pharmaceutical and Hanchang Group also reached the daily limit up [1] - Other companies such as Hite Bio, Anke Bio, Huisheng Bio, Zhendong Pharmaceutical, Tebao Bio, and Zhenbaodao saw increases of over 5% [1]

证券之星消息，7月30日动物保健板块较上一交易日下跌0.46%，生物股份领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.98 | 7.65% | 7.08万 | 7555.51万 | | | 002868 | *ST绿康 | 26.73 | 4.99% | 2.78万 | 7294.48万 | | | 839729 | 永顺生物 | 10.02 | 1.83% | 4.19万 | 4168.45万 | | | 300871 | 回盛生物 | 22.22 | 1.37% | 16.18万 | | 3.63亿 | | 002688 | 金河生物 | 7.22 | 0.84% | 42.68万 | | 3.06亿 | | 688098 | 申联生物 | 6.90 | 0.73% | 10.01万 | 6919.84 ...

Group 1 - The core viewpoint of the news is that Hubei Kewen Biological Technology Co., Ltd. (回盛生物) has shown significant financial growth in its latest quarterly report, with a total revenue of 399 million yuan, representing a year-on-year increase of 92.96% [1] - The company's net profit attributable to shareholders reached 44.5 million yuan, a remarkable year-on-year growth of 371.23% [1] - The company has a current ratio of 1.420 and a quick ratio of 1.162, indicating a strong liquidity position, while its debt-to-asset ratio stands at 47.97% [1] Group 2 - Hubei Kewen Biological has made investments in 13 companies and participated in 50 bidding projects, showcasing its active engagement in the market [2] - The company holds 115 trademark registrations and 63 patents, reflecting its commitment to intellectual property and innovation [2] - Additionally, the company possesses 47 administrative licenses, indicating its compliance and operational capabilities within the industry [2]

从资金流向上来看，当日动物保健板块主力资金净流出9984.08万元，游资资金净流出2164.17万元，散户 资金净流入1.21亿元。动物保健板块个股资金流向见下表： 证券之星消息，7月29日动物保健板块较上一交易日下跌0.5%，驱动力领跌。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 25.46 | 2.91% | 2.25万 | | 5731.13万 | | 688098 | 申联生物 | 6.85 | 1.33% | 10.41万 | | 7137.24万 | | 603566 | 普莱柯 | 15.23 | 0.40% | 5.03万 | | 7579.24万 | | 002688 | 金河生物 | 7.16 | 0.14% | 36.15万 | | 2.59亿 | | 688526 | 科前生物 | 17.2 ...

Group 1 - The A-share pet economy sector showed strong performance at the beginning of trading, with Kangtai Medical rising over 14% [1] - Rainbow Group and Huisheng Biological both increased by over 5% [1] - Other companies such as Jiaotong Angli, Hasi Lian, Yiyi Co., and Guai Bao Pet also experienced gains [1]

Core Views - The breeding sector is experiencing improved supply-demand dynamics due to intensified policy regulation, with measures from the National Development and Reform Commission (NDRC) aimed at optimizing pig production capacity, which is expected to enhance CPI targets and stabilize pig prices [4][50] - The beef industry is undergoing significant supply reduction, with a deep cycle anticipated as the number of breeding cows declines sharply, leading to lower beef supply starting in the second half of 2025 [6][88] - Smart agriculture is benefiting from ongoing policy incentives and increased funding, with water conservancy investments projected to reach 1.4 trillion yuan in 2024, marking a 12.8% year-on-year increase [6][50] Breeding Sector - The breeding industry is seeing a favorable supply-demand balance, with policies aimed at controlling production capacity and improving profitability for leading companies such as Muyuan Foods and Wens Foodstuffs [4][50] - The profitability of self-breeding operations is stable, while external pig purchases show fluctuating profits, indicating a need for careful management of breeding strategies [20][25] - The average weight of pigs being slaughtered has decreased, which is expected to reduce supply pressure and potentially increase pig prices in the coming months [41][42] Beef Industry - The domestic beef supply is expected to decrease significantly due to a reduction in breeding cow numbers, with the industry mirroring the pre-2019 pig cycle in terms of supply adjustments [6][88] - The beef market is characterized by a long adjustment period from breeding to market, typically requiring 2-3 years, which complicates supply management [70] Smart Agriculture - The smart agriculture sector is poised for growth driven by government policies and funding, with a focus on modernizing irrigation systems and enhancing water management practices [6][50] - The market for smart agriculture is projected to expand significantly, with the government aiming to establish 13 million acres of efficient water-saving irrigation [6] Animal Health - The veterinary drug sector is experiencing a structural shift due to the implementation of new GMP standards, which are raising industry entry barriers and promoting consolidation among leading firms [51][66] - The veterinary raw material drug prices are entering a recovery phase after a prolonged downturn, with demand expected to rise as breeding profitability improves [53][66] Investment Recommendations - Key investment targets include Muyuan Foods, Wens Foodstuffs, and Jiusan Foods in the breeding sector, as well as Deyu Water Saving and Ruipu Biological in the smart agriculture and animal health sectors, respectively [4][66][67]